Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

兴齐眼药公告，预计2025年度归属于上市公司股东的净利润为6.62亿元-7.49亿元，比上年同期增长 95.82%-121.56%。报告期内，公司坚持自主研发，巩固核心竞争优势，加大市场拓展力度，持续优化产 品结构，深化成本费用管控，推动整体盈利能力提升，经营业绩延续良好增长态势。 (本文来自第一财经) ...

人民财讯1月22日电，兴齐眼药（300573）1月22日发布业绩预告，预计2025年归母净利润6.62亿元— 7.49亿元，同比增长95.82%—121.56%。报告期内，公司坚持自主研发，加大市场拓展力度，持续优化 产品结构，深化成本费用管控，推动整体盈利能力提升，公司营业收入及净利润均保持稳定增长，经营 业绩延续良好增长态势。 ...

兴齐眼药公告，预计2025年度净利润为6.62亿元～7.49亿元，同比增长95.82%～121.56%。报告期内， 公司坚持自主研发，巩固核心竞争优势，加大市场拓展力度，持续优化产品结构，深化成本费用管控， 推动整体盈利能力提升，公司营业收入及净利润均保持稳定增长，经营业绩延续良好增长态势。 ...

每经AI快讯，1月22日，兴齐眼药（300573）(300573.SZ)发布2025年度业绩预告，预计归属于上市公司 股东的净利润为6.62亿元~7.49亿元，比上年同期增长95.82%~121.56%。报告期内，公司坚持自主研 发，巩固核心竞争优势，加大市场拓展力度，持续优化产品结构，深化成本费用管控，推动整体盈利能 力提升，经营业绩延续良好增长态势。 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2026-003 沈阳兴齐眼药股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 预计净利润为正值且属于下列情形之一： 单位：万元 | 项 | 目 | | | 本报告期 | | 上年同期 | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | | 66,200 | | ～ | 74,900 | 33,806.18 | | | | 比上年同期增长 | 95.82% | ～ | 121.56% | | | 扣除非经常性损 益后的净利润 | | 66,200 | | ～ | 74,900 | 34,754.25 | | | | 比上年同期增长 | 90.48% | ～ | 115.51% | | 二、与会计师事务所沟通情况 公司已就业绩预告有关事项与会计师事务所进行预沟通，双方在 ...

证券之星消息，1月22日化学制药板块较上一交易日下跌1.01%，益方生物领跌。当日上证指数报收于 4122.58，上涨0.14%。深证成指报收于14327.05，上涨0.5%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 605177 | 东亚药业 | 22.95 | 6.89% | 6.39万 | | 1.45亿 | | 688799 | 华纳药厂 | 50.35 | 6.52% | 7.58万 | | 3.74亿 | | 600851 | 海欣股份 | 8.00 | 5.26% | 52.68万 | | 4.27亿 | | 002898 | *ST赛隆 | 14.16 | 4.97% | - 3.32万 | | 4572.87万 | | 688356 | 键凯科技 | 107.48 | 3.29% | 1.27万 | | 1.36亿 | | 300401 | 化园生物 | 18.61 | 3.10% | 40.89万 | | 7.64亿 | | ...

Group 1 - The A-share market saw a significant decline in innovative drug concept stocks, with notable drops including Aidi Pharmaceutical down over 11% and Yifang Bio down over 5% [1] - Other companies such as Xingqi Pharmaceutical, Zhenbaodao, and Dize Pharmaceutical experienced declines of over 4%, while Rongchang Bio, Hanshang Group, Yuekang Pharmaceutical, Xinlitai, Haishike, Shanghai Yizhong, and Kanghong Pharmaceutical fell by over 3% [1] Group 2 - Aidi Pharmaceutical (688488) reported a decline of 11.33%, with a total market value of 7.835 billion and a year-to-date increase of 14.02% [2] - Yifang Bio (688382) decreased by 5.99%, with a market capitalization of 15 billion and a year-to-date decline of 4.99% [2] - Xingqi Pharmaceutical (300573) fell by 4.82%, with a market value of 19.4 billion and a year-to-date increase of 12.01% [2] - Zhenbaodao (603567) dropped by 4.74%, with a market capitalization of 7.951 billion and a year-to-date decline of 5.38% [2] - Dize Pharmaceutical (688192) decreased by 4.19%, with a market value of 27.5 billion and a year-to-date increase of 2.78% [2] - Rongchang Bio (688331) fell by 3.98%, with a market capitalization of 56.1 billion and a year-to-date increase of 27.79% [2] - Hanshang Group (600774) decreased by 3.93%, with a market value of 3.101 billion and a year-to-date increase of 14.99% [2] - Yuekang Pharmaceutical (688658) dropped by 3.84%, with a market capitalization of 12 billion and a year-to-date increase of 18.40% [2] - Xinlitai (002294) fell by 3.32%, with a market value of 55.5 billion and a year-to-date increase of 0.48% [2] - Haishike (002653) decreased by 3.23%, with a market capitalization of 56.1 billion and a year-to-date decline of 2.44% [2] - Shanghai Yizhong (688091) dropped by 3.17%, with a market value of 11.2 billion and a year-to-date increase of 15.60% [2] - Kanghong Pharmaceutical (002773) fell by 3.15%, with a market capitalization of 29.5 billion and a year-to-date increase of 6.81% [2]

证券日报网讯1月21日，兴齐眼药（300573）在互动平台回答投资者提问时表示，如公司符合业绩预告 的披露条件，公司将在2026年1月31日前履行2025年度业绩预告的披露义务。 ...

当日关注点 来自交易信息汇总：1月20日主力资金净流入4670.78万元，显示主力对兴齐眼药的积极介入。 交易信息汇总资金流向 截至2026年1月20日收盘，兴齐眼药(300573)报收于81.38元，上涨1.81%，换手率7.65%，成交量14.49万 手，成交额11.62亿元。 董秘最新回复 投资者： 你好，董秘，我是一直坚定投资兴齐眼的投资者，我想问一下，兴齐眼药，属于儿童用药， 可以走优先审批的路线，贵公司是否有考虑？优先纳入医保，而且现在有独家的优势，价格谈判起来会 更加的容易，为了加速提高渗透率的角度去考虑，还是说贵公司会继续先观望，请问公司在争取医保这 件事的是怎么看待的 董秘： 尊敬的投资者您好，公司将根据国家医保政策并结合市场情况做出合适的决策。感谢您的关 注。 投资者： 我想问一下，贵公司什么时候会开展国际路线，是否有打算同步开展，在欧美市场，0.01%阿 托品在美国开启临床试验，同步申请欧盟EMA注册；2027年争取获批，进入全球最大近视防控市场， 请问是否有这方面的考量？ 董秘： 尊敬的投资者您好，公司当前主营业务聚焦于国内市场，相关海外合作事宜尚处于沟通洽谈阶 段，达到信息披露节点时 ...